Global Monoclonal Antibody Therapy Market

Monoclonal Antibody Therapy Market Size, Share, Growth Analysis, By Type(Murine Antibodies, Chimeric Antibodies, Humanised Antibodies and Fully Human Antibodies), By Application(Oncology, Autoimmune Diseases, Infectious Diseases, Inflammatory Conditions and Others.), By Region - Industry Forecast 2025-2032

Report ID: SQMIG35A2527 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 64 | Figures: 75

Monoclonal Antibody Therapy Market Competitive Landscape

The global monoclonal antibody therapy market is highly competitive and dynamic, characterised by the presence of numerous pharmaceutical and biotechnology companies. Monoclonal antibody therapy has gained significant traction in the healthcare industry due to its targeted approach and effectiveness in treating various diseases, including cancer, autoimmune disorders, and infectious diseases. The competitive landscape of this market is shaped by factors such as research and development activities, product portfolio, strategic collaborations, and regulatory approvals.

Monoclonal Antibody Therapy Market Top Player’s Company Profiles

  • Roche Holding AG (Switzerland)
  • Johnson & Johnson (US)
  • Novartis International AG (Switzerland)
  • Pfizer Inc. (US)
  • Merck & Co., Inc. (US)
  • Amgen Inc. (US)
  • AstraZeneca PLC (UK)
  • Bristol Myers Squibb Company (US)
  • AbbVie Inc. (US)
  • Eli Lilly and Company (US)
  • Sanofi S.A. (France)
  • GlaxoSmithKline plc (UK)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Biogen Inc. (US)
  • Regeneron Pharmaceuticals, Inc. (US)
  • Moderna, Inc. (US)
  • BioNTech SE (Germany)
  • Alexion Pharmaceuticals, Inc. (US)
  • Gilead Sciences, Inc. (US)
  • CSL Limited (Australia)

Monoclonal Antibody Therapy Market

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Monoclonal Antibody Therapy Market size was valued at USD 143.56 Billion in 2022 and is poised to grow from USD 154.05 Billion in 2023 to USD 270.68 Billion by 2031, at a CAGR of 7.3% during the forecast period (2023-2030).

The global monoclonal antibody therapy market is highly competitive and dynamic, characterised by the presence of numerous pharmaceutical and biotechnology companies. Monoclonal antibody therapy has gained significant traction in the healthcare industry due to its targeted approach and effectiveness in treating various diseases, including cancer, autoimmune disorders, and infectious diseases. The competitive landscape of this market is shaped by factors such as research and development activities, product portfolio, strategic collaborations, and regulatory approvals. 'Roche Holding AG (Switzerland)', 'Johnson & Johnson (US)', 'Novartis International AG (Switzerland)', 'Pfizer Inc. (US)', 'Merck & Co., Inc. (US)', 'Amgen Inc. (US)', 'AstraZeneca PLC (UK)', 'Bristol Myers Squibb Company (US)', 'AbbVie Inc. (US)', 'Eli Lilly and Company (US)', 'Sanofi S.A. (France)', 'GlaxoSmithKline plc (UK)', 'Takeda Pharmaceutical Company Limited (Japan)', 'Biogen Inc. (US)', 'Regeneron Pharmaceuticals, Inc. (US)', 'Moderna, Inc. (US)', 'BioNTech SE (Germany)', 'Alexion Pharmaceuticals, Inc. (US)', 'Gilead Sciences, Inc. (US)', 'CSL Limited (Australia)'

Significant progress in biotechnology and genetic engineering has played a pivotal role in the development of advanced monoclonal antibody therapies. These advancements have facilitated the engineering of antibodies with improved specificity, efficacy, and reduced side effects. Through techniques such as genetic manipulation, researchers can optimise monoclonal antibodies for specific targets, enhancing their therapeutic potential. These breakthroughs have broadened the range of applications for monoclonal antibody therapies and increased their success rates.

Increasing Adoption and Development of Personalised and Targeted Therapies: Monoclonal antibody therapies have gained significant momentum in the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases. Personalised medicine approaches, such as companion diagnostics, genetic profiling, and biomarker identification, are being integrated into the development and prescription of monoclonal antibody therapies. This trend allows for a more precise and tailored treatment approach, maximising therapeutic efficacy while minimising adverse effects.

In the global monoclonal antibody therapy market, the most dominant region is North America. North America has a strong presence in the market due to factors such as well-established healthcare infrastructure, advanced research and development facilities, and a high adoption rate of monoclonal antibody therapies. The region is home to several prominent pharmaceutical companies and biotechnology firms that are actively involved in the development and commercialization of monoclonal antibody therapies. Additionally, favourable reimbursement policies and government support for innovative therapies contribute to the dominance of North America in the market.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Monoclonal Antibodies Market
Buy Now GET FREE SAMPLE
Antibody Production Market
Buy Now GET FREE SAMPLE
Research Antibodies and Reagents Market
Buy Now GET FREE SAMPLE
Immunoglobulin Market
Buy Now GET FREE SAMPLE
Therapeutic Vaccines Market
Buy Now GET FREE SAMPLE
Targeted Therapeutics Market
Buy Now GET FREE SAMPLE
Cell Therapy Market
Buy Now GET FREE SAMPLE
Intravenous Immunoglobulin Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Monoclonal Antibody Therapy Market

Report ID: SQMIG35A2527

$5,300
BUY NOW GET FREE SAMPLE